NYSE:EW - Edwards Lifesciences Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$145.42 -1.90 (-1.29 %)
(As of 10/19/2018 04:00 PM ET)
Previous Close$147.32
Today's Range$145.18 - $149.07
52-Week Range$100.20 - $175.00
Volume4.32 million shs
Average Volume2.26 million shs
Market Capitalization$30.85 billion
P/E Ratio34.74
Dividend YieldN/A
Beta0.57
Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings and the beating-heart mitral repair systems; and cardiac cannula devices, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function in surgical and intensive care settings; pulmonary artery catheters; Oximetry Central Venous catheters, as well as clinical monitoring platforms that display a patient's physiological status; and disposable pressure monitoring devices and closed blood sampling systems to protect patients and clinicians from infection. The company distributes its products through direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1999 and is headquartered in Irvine, California.

Receive EW News and Ratings via Email

Sign-up to receive the latest news and ratings for EW and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Surgical appliances & supplies
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNYSE:EW
CUSIP28176E10
Phone949-250-2500

Debt

Debt-to-Equity Ratio0.19
Current Ratio1.86
Quick Ratio1.47

Price-To-Earnings

Trailing P/E Ratio34.74
Forward P/E Ratio31.14
P/E Growth2.03

Sales & Book Value

Annual Sales$3.44 billion
Price / Sales8.86
Cash Flow$4.2053 per share
Price / Cash34.58
Book Value$13.97 per share
Price / Book10.41

Profitability

EPS (Most Recent Fiscal Year)$3.80
Net Income$583.60 million
Net Margins19.59%
Return on Equity29.11%
Return on Assets16.07%

Miscellaneous

Employees12,200
Outstanding Shares209,390,000
Market Cap$30.85 billion

Edwards Lifesciences (NYSE:EW) Frequently Asked Questions

What is Edwards Lifesciences' stock symbol?

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

When did Edwards Lifesciences' stock split? How did Edwards Lifesciences' stock split work?

Edwards Lifesciences shares split on Monday, December 14th 2015. The 2-1 split was announced on Thursday, November 19th 2015. The newly created shares were payable to shareholders after the market closes on Friday, December 11th 2015. An investor that had 100 shares of Edwards Lifesciences stock prior to the split would have 200 shares after the split.

How will Edwards Lifesciences' stock buyback program work?

Edwards Lifesciences announced that its board has approved a stock buyback plan on Thursday, December 7th 2017, which allows the company to buyback $1,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to purchase shares of its stock through open market purchases. Stock buyback plans are often a sign that the company's board of directors believes its stock is undervalued.

How were Edwards Lifesciences' earnings last quarter?

Edwards Lifesciences Corp (NYSE:EW) released its earnings results on Thursday, July, 26th. The medical research company reported $1.24 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.13 by $0.11. The medical research company had revenue of $972 million for the quarter, compared to analysts' expectations of $968.32 million. Edwards Lifesciences had a return on equity of 29.11% and a net margin of 19.59%. The business's quarterly revenue was up 10.0% compared to the same quarter last year. During the same period last year, the company posted $1.08 earnings per share. View Edwards Lifesciences' Earnings History.

When is Edwards Lifesciences' next earnings date?

Edwards Lifesciences is scheduled to release their next quarterly earnings announcement on Tuesday, October 23rd 2018. View Earnings Estimates for Edwards Lifesciences.

How can I listen to Edwards Lifesciences' earnings call?

Edwards Lifesciences will be holding an earnings conference call on Tuesday, October 23rd at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8777042848.

What guidance has Edwards Lifesciences issued on next quarter's earnings?

Edwards Lifesciences updated its FY18 earnings guidance on Thursday, July, 26th. The company provided earnings per share (EPS) guidance of $4.60-4.75 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.63. The company issued revenue guidance of high end of $3.5-3.9 billion, compared to the consensus revenue estimate of $3.84 billion.Edwards Lifesciences also updated its Q3 guidance to $0.93-1.03 EPS.

What price target have analysts set for EW?

20 brokerages have issued twelve-month price targets for Edwards Lifesciences' shares. Their forecasts range from $115.00 to $200.00. On average, they expect Edwards Lifesciences' share price to reach $153.1053 in the next year. This suggests a possible upside of 5.3% from the stock's current price. View Analyst Price Targets for Edwards Lifesciences.

What is the consensus analysts' recommendation for Edwards Lifesciences?

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 2 sell ratings, 6 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Edwards Lifesciences.

What are Wall Street analysts saying about Edwards Lifesciences stock?

Here are some recent quotes from research analysts about Edwards Lifesciences stock:
  • 1. Northland Securities analysts commented, "We analyze data on MitraClip + GDMT in HFpEF / HFrEF + FMR, & impact on existing clinical trials in both transcatheter mitral repair / replacement programs. There are a ton of unknowns, however, it is likely that: 1) Edwards PASCAL trial will need to be redesigned with MitraClip as the control (even though the trial is in DMR; Medtronic’ APOLLO trial, especially in HFrEF might" not need MitraClip as the comparator). 2) COAPT results are not applicable in real-world setting. Key Points We confess, we don’t have access to raw data in COAPT, hence it is impossible to make definitive arguments." (10/11/2018)
  • 2. According to Zacks Investment Research, "Over the past year, Edwards Lifesciences has outperformed its industry. The company continues to see strong transcatheter valve sales in the domestic market as well as overseas.  Edwards Lifesciences' raised 2018 EPS guidance buoys optimism. Further, management seems to be upbeat about CMS opening a National Coverage Analysis to reconsider the National Coverage Determination released in 2012 for transcatheter aortic valve replacement. The company expects to gain traction in the ever-expanding TAVR market based on increasing preference for transcatheter aortic valve replacement as well as compelling clinical evidence. Management believes that the huge untapped potential in emerging markets is likely to act as a positive catalyst. The company is striving to strengthen its hold in the markets of Asia, especially Japan. However, tough competitive landscape and reimbursement issues continue to pose challenges." (9/26/2018)

Who are some of Edwards Lifesciences' key competitors?

Who are Edwards Lifesciences' key executives?

Edwards Lifesciences' management team includes the folowing people:
  • Mr. Michael A. Mussallem, Chairman & CEO (Age 65)
  • Mr. Scott B. Ullem, Corp. VP & CFO (Age 51)
  • Mr. Donald E. Bobo Jr., Corp. VP of Strategy & Corp. Devel. (Age 56)
  • Mr. Larry L. Wood, Corp. VP of Transcatheter Heart Valve (Age 52)
  • Ms. Catherine M. Szyman, Corp. VP of Critical Care (Age 51)

Who are Edwards Lifesciences' major shareholders?

Edwards Lifesciences' stock is owned by many different of retail and institutional investors. Top institutional shareholders include MERIAN GLOBAL INVESTORS UK Ltd (0.50%), Hardman Johnston Global Advisors LLC (0.16%), Strs Ohio (0.13%), Huntington National Bank (0.12%), Bank of Montreal Can (0.12%) and Scout Investments Inc. (0.12%). Company insiders that own Edwards Lifesciences stock include Bernard J Zovighian, Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Dylan Sidoo, Huimin Wang, Jean-Luc M Lemercier, Kieran Gallahue, Larry L Wood, Michael A Mussallem, Patrick B Verguet, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link. View Institutional Ownership Trends for Edwards Lifesciences.

Which institutional investors are selling Edwards Lifesciences stock?

EW stock was sold by a variety of institutional investors in the last quarter, including Cornerstone Wealth Management LLC, State of New Jersey Common Pension Fund D, Strs Ohio, Barometer Capital Management Inc., Cookson Peirce & Co. Inc., Hardman Johnston Global Advisors LLC, Winslow Evans & Crocker Inc. and Kovack Advisors Inc.. Company insiders that have sold Edwards Lifesciences company stock in the last year include Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link. View Insider Buying and Selling for Edwards Lifesciences.

Which institutional investors are buying Edwards Lifesciences stock?

EW stock was bought by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd, Scout Investments Inc., Varma Mutual Pension Insurance Co, Bank of Montreal Can, First American Bank, Huntington National Bank, HWG Holdings LP and Capital Insight Partners LLC. Company insiders that have bought Edwards Lifesciences stock in the last two years include Catherine M Szyman, Dylan Sidoo and Kieran Gallahue. View Insider Buying and Selling for Edwards Lifesciences.

How do I buy shares of Edwards Lifesciences?

Shares of EW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Edwards Lifesciences' stock price today?

One share of EW stock can currently be purchased for approximately $145.42.

How big of a company is Edwards Lifesciences?

Edwards Lifesciences has a market capitalization of $31.12 billion and generates $3.44 billion in revenue each year. The medical research company earns $583.60 million in net income (profit) each year or $3.80 on an earnings per share basis. Edwards Lifesciences employs 12,200 workers across the globe.

What is Edwards Lifesciences' official website?

The official website for Edwards Lifesciences is http://www.edwards.com.

How can I contact Edwards Lifesciences?

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The medical research company can be reached via phone at 949-250-2500 or via email at [email protected]


MarketBeat Community Rating for Edwards Lifesciences (NYSE EW)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  1,002 (Vote Outperform)
Underperform Votes:  712 (Vote Underperform)
Total Votes:  1,714
MarketBeat's community ratings are surveys of what our community members think about Edwards Lifesciences and other stocks. Vote "Outperform" if you believe EW will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EW will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel